GGrantIndex
← Leaderboards

Emily L Germain-Lee

Johns Hopkins University

$2,572,486
Attributed
$4,059,242
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $914.6K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,444,352 · 6
FDA$614,890 · 2

By mechanism

R01$3,094,879 · 3
R21$944,903 · 2
M01$19,460 · 3

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Tissues

Research focus

TissuesSignal TransductionPhysiologicalBone DensityPlaySignal PathwaySignaling MoleculeAffectBone LossNovel Therapeutic InterventionBone StructurePreventGenetic ApproachClinical ApplicationBone MassBoneNamesHomeostasisMolecularObesityHormonesGrowthLoxp-Flanked AlleleActivins

Grant awards (22)

Extracellular regulation of bone mass by transforming growth factor-ß-related ligands and their binding proteins$607,748
R01 · FY2025 · AR
Extracellular regulation of bone mass by transforming growth factor-ß-related ligands and their binding proteins$607,748
R01 · FY2024 · AR
Extracellular regulation of bone mass by transforming growth factor-ß-related ligands and their binding proteins$625,600
R01 · FY2023 · AR
Elucidating extragonadal functions of follicle stimulating hormone using genetic approaches in mice$217,852
R21 · FY2023 · AG · contact PI
Extracellular regulation of bone mass by transforming growth factor-ß-related ligands and their binding proteins$638,893
R01 · FY2022 · AR
Elucidating extragonadal functions of follicle stimulating hormone using genetic approaches in mice$275,671
R21 · FY2022 · AG · contact PI
The role of G protein-coupled signaling in neurocognitive and psychosocialabnormalities$211,444
R21 · FY2017 · HD · contact PI
The role of G protein-coupled signaling in neurocognitive and psychosocial abnormalities$122,653
R21 · FY2016 · HD · contact PI
The role of G protein-coupled signaling in neurocognitive and psychosocialabnormalities$117,283
R21 · FY2016 · HD · contact PI
Phase 2 of Growth Hormone for Treatment of Albright Hereditary Osteodystrophy$96,524
R01 · FY2013 · FD · contact PI
Phase 2 of Growth Hormone for Treatment of Albright Hereditary Osteodystrophy$139,020
R01 · FY2011 · FD · contact PI
Phase 2 of Growth Hormone for Treatment of Albright Hereditary Osteodystrophy$123,891
R01 · FY2010 · FD · contact PI
Growth Hormone Use in Pseudohypoparathyroidism Type 1A$34,311
R01 · FY2008 · FD · contact PI
Growth Hormone Use in Pseudohypoparathyroidism Type 1A$43,960
R01 · FY2007 · FD · contact PI
STUDIES OF HORMONE ACTION IN PATIENTS WITH ALTERED G PROTEIN FUNCTION$1,650
M01 · FY2007 · RR · contact PI
Growth Hormone Use in Pseudohypoparathyroidism Type 1A$112,931
R01 · FY2006 · FD · contact PI
Growth Hormone Use in Pseudohypoparathyroidism Type 1A$64,253
R01 · FY2006 · FD · contact PI
STUDIES OF HORMONE ACTION IN PATIENTS WITH ALTERED G PROTEIN FUNCTION$5,206
M01 · FY2006 · RR · contact PI
STUDIES OF HORMONE ACTION IN PATIENTS WITH ALTERED G PROTEIN FUNCTION$9,470
M01 · FY2005 · RR
Growth Hormone Use in Pseudohypoparathyroidism Type 1A$0
R01 · FY2005 · FD
Studies of Hormone Action in Patients with Altered G Protein Function$3,134
M01 · FY2004 · RR
Growth Hormone Use in Pseudohypoparathyroidism Type 1A$0
R01 · FY2004 · FD